Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Candel Therapeutics (CADL) EBT (2020 - 2023)

Candel Therapeutics' EBT history spans 4 years, with the latest figure at -$10.6 million for Q4 2023.

  • For Q4 2023, EBT fell 37.35% year-over-year to -$10.6 million; the TTM value through Dec 2023 reached -$38.9 million, down 12.44%, while the annual FY2024 figure was -$30.2 million, 22.39% up from the prior year.
  • EBT for Q4 2023 was -$10.6 million at Candel Therapeutics, down from -$9.0 million in the prior quarter.
  • Across five years, EBT topped out at -$2.6 million in Q2 2020 and bottomed at -$10.6 million in Q4 2023.
  • The 4-year median for EBT is -$8.4 million (2021), against an average of -$7.7 million.
  • The largest annual shift saw EBT plummeted 103.02% in 2021 before it increased 0.65% in 2022.
  • A 4-year view of EBT shows it stood at -$6.1 million in 2020, then fell by 27.53% to -$7.8 million in 2021, then grew by 0.65% to -$7.7 million in 2022, then plummeted by 37.35% to -$10.6 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's EBT are -$10.6 million (Q4 2023), -$9.0 million (Q3 2023), and -$9.8 million (Q2 2023).